Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
11C-L-deprenyl-D2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO4602522 Group 1 | EXPERIMENTAL | - |
| RO4602522 Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 11C-L-deprenyl-D2 | DRUG | Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total |
| RO4602522 | DRUG | Multiple doses of RO4602522 for 14 days |
Inclusion Criteria: General: * Adults between 50-80 years of age. Females must be of non-child-bearing potential or if of child-bearing potential must use an acceptable form of contraception * Body mass index (BMI) 18.0-32.0 kg/m2 inclusive Healthy volunteers: * Healthy, with no clinically relev...
11C-L-deprenyl-D2 is an investigational small molecule being studied for use in healthy volunteers and in patients with Alzheimer's disease. It is a positron emission tomography (PET) tracer, meaning it is designed to be used in imaging to visualize biological processes in the body. The drug is currently in Phase 1 clinical development.
11C-L-deprenyl-D2 is being studied for use in Alzheimer's disease as a diagnostic imaging agent. It is intended to be used with PET scans to help visualize or measure certain aspects of the disease. The drug is in Phase 1 clinical trials to evaluate its safety and how it behaves in the body.
11C-L-deprenyl-D2 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical research to evaluate the drug's potential as a diagnostic tool.
11C-L-deprenyl-D2 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and potential uses. The drug is not yet available for clinical use outside of research settings.
11C-L-deprenyl-D2 has been studied in one clinical trial, identified as NCT01701089. This Phase 1 study, titled 'A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers,' was conducted in Sweden and enrolled 17 participants aged 50 years and older. The trial has been completed.
Yes, 11C-L-deprenyl-D2 is also known as RO4602522. The clinical trial NCT01701089, which studied the drug, used the name RO4602522 in its title. Both names refer to the same investigational compound being developed by Roche.